Figure 2.
Major metabolic effects of blebbistatin on perfused hearts. Left: beating hearts perfused with crystalloid buffers may have significant IKATP due to low ATP/ADP ratio, which can shorten the action potential duration. Right: blebbistatin treatment reduces metabolic demand, increases ATP/ADP ratio, and may decrease IKATP, resulting in a longer action potential duration. Coronary flow is also typically reduced under these conditions. Notably, intracellular calcium transients are minimally affected by blebbistatin. AP, action potential; Ca2+, intracellular calcium transient; IKATP, ATP-sensitive potassium channel current. Created with BioRender.com, and published with permission.